Skip to main content

SuperMicrobiologists

New PDA Technical Report 33: What Changes for Rapid Microbiological Methods? 

Published on 15 July 2026 4 min


This article is also available as a podcast in more than 20 languages. Click the ⚙️ Settings icon on YouTube, then choose Audio Track and Subtitles to watch it in your preferred language.



For pharmaceutical microbiologists looking to validate a Rapid Microbiological Method (RMM), one document stands out as a true roadmap: PDA Technical Report 33 from USP.

To better understand this guidance document and the major changes introduced in its new edition (2026), we interviewed its chair, Michael Miller.

Here’s what he told us about the new PDA Technical Report 33.


Discover the Top 4 Rapid Micro Methods

We asked the SuperMicrobiologists in a big survey.
Here’s what they said.




Can you first tell us what is PDA Technical Report 33?

Michael : Technical Report 33 was first published by the PDA in 2000. It was one of the first guidance documents dedicated to Rapid and Alternative Microbiological Methods and provided companies with a roadmap for implementing these technologies.

It covers technology selection, validation strategies, regulatory considerations and the different applications of rapid methods, whether for sterility testing, bioburden testing, environmental monitoring, water testing or in-process controls.

The previous revision was published in 2013, and I had the opportunity to chair that revision. At that time, the industry needed additional guidance because regulatory expectations were evolving, pharmacopoeias were becoming more involved and more companies were starting to implement rapid microbiological methods.


Why did the industry need a new version?

A great deal has changed since 2013.

First, regulatory authorities around the world have become much more familiar with rapid and alternative microbiological methods. Many of them now actively encourage their use because they improve product quality and patient safety.

Second, the pharmacopoeias have expanded their own guidance with new chapters dedicated to alternative technologies.

Third, and perhaps most importantly, the pharmaceutical industry itself has changed. We are now manufacturing products that simply didn’t exist when the previous report was written.

Cell therapies, gene therapies, ATMPs, radiopharmaceuticals and other short shelf-life medicines all require microbiological results much faster than conventional methods can provide.

The industry needed guidance that reflects both today’s technologies and today’s manufacturing reality.


What has changed the most compared with the 2013 version?

One of the most significant additions is the new statistical guidance.

For many years, one of the biggest challenges has been demonstrating that a rapid or alternative method performs as well as an existing compendial method.

Companies kept asking the same questions:

  • How do we demonstrate comparability?

  • How do we demonstrate non-inferiority?

  • What statistical approaches should we use?

The previous version didn’t provide enough detail in this area.

That’s why the new report includes a comprehensive appendix dedicated entirely to statistical analysis.

It provides recommendations for both quantitative and qualitative methods and explains how to compare a new method with an existing one in a scientifically robust way.

This is especially important because many modern technologies no longer generate CFU results. Instead, they produce fluorescence signals, optical signals or other alternative outputs. The report explains how these new signals can be compared with conventional microbiological data.

We also updated the regulatory sections to reflect today’s expectations, including Annex 1, contamination control strategies and the increasing importance of risk-based decision making within pharmaceutical quality systems.


Who will benefit most from the new TR33?

The report was written for a broad audience.

It will help microbiologists implementing rapid methods for the first time, validation specialists designing studies, quality assurance professionals, suppliers developing new technologies and even management teams that want to better understand the scientific and business value of Rapid Microbiological Methods.

Our goal was to create a practical roadmap that helps people move from interest to successful implementation.


When will it be available?

We completed the final work just last week (mid June 2026), and we expect the official publication within the next few weeks.


UPDATE : PDA TR 33 has been officially published in July 2026. Here it is.


A big thank you to Michael Miller for taking the time to help us better understand the new PDA Technical Report 33.
If you want to learn more about Rapid (and Alternative) Microbiology Methods, be sure to check out his excellent blog here : www.rapidmicromethods.com

Leave a Reply

Your email address will not be published. Required fields are marked *